News & Events about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic...
Avidity Biosciences roared higher after announcing favorable data delivering RNA medicines to muscle tissue.Avidity Biosciences roared higher after announcing favorable data delivering RNA medicines to muscle tissue.Hours after Alex Ovechkin became the first NHL player to score 800 goals with one ...
Business Wire
2 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton...
Business Wire
3 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazines 2022 Top Employer Survey. This marks the fourth year Alnylam was featured as one of the top three companies in the annual survey of more than 6,200...
Business Wire
4 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved a label expansion for OXLUMO (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of...